T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04

被引：0
|
作者：
Tsurutani, Junji [1 ]
Modi, Shanu [2 ]
Sohn, Joo Hyuk [3 ]
Tokunaga, Eriko [4 ]
Niikura, Naoki [5 ]
Park, Yeon Hee [6 ]
Lee, Keun Seok [7 ]
Chae, Yee Soo [8 ]
Wang, Xiaojia [9 ,10 ]
Li, Wei [11 ]
Im, Seock-Ah [12 ]
Xu, Binghe [13 ]
Lu, Yen-Shen [14 ]
Gambhire, Dhiraj [15 ]
Nishijima, Soichiro [16 ]
Nishiyama, Yuji [16 ]
Sugihara, Masahiro [16 ,17 ]
机构：
[1] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Yonsei Canc Ctr, Seoul, South Korea
[4] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[5] Tokai Univ, Hiratsuka, Kanagawa, Japan
[6] Samsung Med Ctr, Seoul, South Korea
[7] Natl Canc Ctr, Gyeonggi Do, South Korea
[8] Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea
[9] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[10] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China
[11] 1st Hosp Jilin Univ, Changchun, Peoples R China
[12] Seoul Natl Univ Hosp, Seoul, South Korea
[13] CAMS, Canc Inst & Hosp, Beijing, Peoples R China
[14] Natl Taiwan Univ Hosp, Taipei, Taiwan
[15] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[16] Daiichi Sankyo Co Ltd, Tokyo, Japan
[17] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS2-2
引用
收藏
页码：S1379 / S1379
页数：1
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Wang, Xiaojia
    Xu, Binghe
    Gambhire, Dhiraj
    Yung, Lotus
    Meinhardt, Gerold
    Wang, Yibin
    Harbeck, Nadia
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [2] Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04
    Prat, Aleix
    Modi, Shanu
    Tsurutani, Junji
    Cameron, David
    Harbeck, Nadia
    Garrido, Charo
    Karnoub, Maha
    Hsu, Ching
    Feng, Wenquin
    Yung, Lotus
    Wang, Yibin
    Gambhire, Dhiraj
    Ford, Shirin K.
    Vitazka, Patrik
    Ueno, Naoto T.
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Determination of HER2-Low Status in Tumors of Patients With Unresectable and/or Metastatic Breast Cancer in DESTINY-Breast04
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 8 - 9
  • [4] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
    Modi, S.
    Jacot, W.
    Iwata, H.
    Park, Y. H.
    Vidal Losada, M. J.
    Li, W.
    Tsurutani, J.
    Zaman, K.
    Ueno, N. T.
    Prat, A.
    Papazisis, K.
    Rugo, H. S.
    Harbeck, N.
    Im, S-A.
    De Laurentiis, M.
    Orbegoso, C. M. A.
    Yung, L.
    Cheng, F-C.
    Cheng, Y.
    Cameron, D. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S334 - S335
  • [5] Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
    Harbeck, Nadia
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Vidal, Maria
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Niikura, Naoki
    Xu, Binghe
    Rugo, Hope
    Papazisis, Konstantinos
    Cortes, Javier
    Krop, Ian
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Cameron, David
    CANCER RESEARCH, 2023, 83 (05)
  • [6] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04
    Modi, Shanu
    Niikura, Naoki
    Yamashita, Toshinari
    Jacot, William
    Sohn, Joohyuk
    Tokunaga, Eriko
    Vidal, Maria Jesus
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yeesoo
    Ueno, Naoto T.
    Prat, Aleix
    Suto, Fumitaka
    Kuwahara, Yusuke
    McEwen, Robert
    Feng, Wenqin
    Goto, Hiroki
    Orbegoso, Cecilia
    Cameron, David A.
    Tsurutani, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
    Tsurutani, J.
    Jacot, W.
    Yamashita, T.
    Riaz, F.
    Yerushalmi, R.
    Im, S-A.
    Niikura, N.
    Halser-Strub, U.
    Cortes, J.
    Wennstig, A-K.
    Chae, Y.
    Wang, X.
    Li, W.
    Simon, H.
    Masci, G.
    Tamburini, E.
    Aguilar, C. Orbegoso
    Tecson, K.
    Yung, L.
    Modi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S342 - S343
  • [8] Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Ueno, N. T.
    Jacot, W.
    Yamashita, T.
    Sohn, J.
    Tokunaga, E.
    Prat, A.
    Tsurutani, J.
    Park, Y. H.
    Rugo, H. S.
    Xu, B.
    Cardoso, F.
    Mitri, Z.
    Mahtani, R.
    Dunton, K.
    Wang, Y.
    Gambhire, D.
    Cottone, F.
    Harbeck, N.
    Cameron, D. A.
    Modi, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S633
  • [9] Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Niikura, Naoki
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yee Soo
    Xu, Binghe
    Wang, Xiaojia
    Im, Seock-Ah
    Li, Wei
    Lu, Yen-Shen
    Aguilar, Cecilia Orbegoso
    Nishijima, Soichiro
    Nishiyama, Yuji
    Sugihara, Masahiro
    Modi, Shanu
    Tsurutani, Junji
    BREAST CANCER, 2024, 31 (05) : 858 - 868
  • [10] Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
    Guarneri, Valentina
    Coelho, Jose Luis Passos
    Duhoux, Francois P.
    Egle, Daniel
    Garcia-Saenz, Jose angel
    Penault-Llorca, Frederique
    Selander, Katri
    Wildiers, Hans
    Zaman, Khalil
    Laeis, Petra
    Lucerna, Markus
    Pierga, Jean-Yves
    FUTURE ONCOLOGY, 2024, 20 (18) : 1237 - 1250
12345